Vyrionix™ Real-Time, Smart Infection Monitoring System
Khyron Technologies, Goleta, California, United States
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: CMOS-FET sensor detects bio-charge current from monoclonal SARS-CoV-2 antibodies bound to viral antigen present in saliva sample providing quantitative viral load count data. Each screen costs ~USD3.00 facilitating at-home screening twice daily. Supports public-venue prospective entrant screening. Highly-scalable CMOS process capable of supporting >100 million screens per month.
Early-stage Startup (Seed)
FIGURES OF MERIT Value Proposition: Approximately $20B COVID-19 Diagnostics market in 2020 accounts mainly for RT-PCR tests and does not account for high implementation costs due to logistics/labor to/from laboratories. TAM for global screening could potentially double market size if consumer-accessible and implemented outside of the highly-regulated medical diagnostics ecosystem. Viral load count data can be digitally transferred to care-providers and RT-PCR diagnosis can be scheduled/arranged prior to symptom onset. Digital privacy and opt-out options available while still being able to generate anonymous, critical, and previously inaccessible epidemiological data (frequency, time, regional density). This type of solution will be ubiquitous for containing future infectious disease management by generating real-time data instead of post-contagion contact tracing.